T&R Biofab KRX:246710KOSDAQ
티앤알바이오팹 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, T&R Biofab reported revenue of ₩9.5bn, up 45.9% year on year, and an operating loss of ₩928m. T&R Biofab (티앤알바이오팹) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 23 with 1 article. The most common catalyst was clinical & approvals (1).
Filing signals 4 quarters of losses Screener
T&R Biofab quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.5bn | +45.9% | −₩928m margin −9.7% | −₩3.8bn |
| Q1 2026 | ₩8.7bn | +46.5% | −₩931m margin −10.7% | −₩1.7bn |
| Q4 2025 derived | ₩7.5bn | +511.9% | −₩2.3bn margin −30.5% | −₩16.6bn |
| Q3 2025 | ₩7.0bn | +534.1% | −₩1.3bn margin −18.2% | −₩5.7bn |
| Q2 2025 | ₩6.5bn | +380.4% | −₩1.9bn margin −29.3% | −₩4.3bn |
| Q1 2025 | ₩6.0bn | +401.5% | −₩3.6bn margin −60.1% | −₩5.4bn |
| Q4 2024 derived | ₩1.2bn | – | −₩2.6bn margin −212.6% | ₩5.8bn |
| Q3 2024 | ₩1.1bn | +15.1% | −₩3.1bn margin −279.2% | −₩4.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
T&R Biofab top stories 2 weeks, by number of outlets
- 1